Eurosurv. Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years o

[tetano]

Eurosurveillance, Volume 22, Issue 4, 26 January 2017
Surveillance and outbreak report

Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season


R Pebody [SUP]1[/SUP] , B Sile [SUP]1[/SUP] , F Warburton [SUP]1[/SUP] , M Sinnathamby [SUP]1[/SUP] , C Tsang [SUP]1[/SUP] , H Zhao [SUP]1[/SUP] , J Ellis [SUP]1[/SUP] , N Andrews [SUP]1[/SUP]
+ Author affiliations
1. National Infection Service, Public Health England, London, United Kingdom


Correspondence: Richard Pebody (richard.pebody@phe.gov.uk)

---

Citation style for this article: Pebody R, Sile B, Warburton F, Sinnathamby M, Tsang C, Zhao H, Ellis J, Andrews N. Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season. Euro Surveill. 2017;22(4)ii=30450. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2017.22.4.30450

Received:09 December 2016; Accepted:18 January 2017

---

[h=4][/h]
The United Kingdom is introducing a universal annual influenza vaccination programme for children. Live attenuated influenza vaccine (LAIV) effectiveness (VE) against laboratory-confirmed influenza hospitalisation in 2 to 6 year-olds in England was measured in 2015/16 using the screening method. VE adjusted for age, geography and month was 54.5% (95% confidence interval (CI): 31.5% to 68.4%) for all influenza types combined; 48.3% (95% CI: 16.9% to 67.8%) for A(H1N1)pdm09 and 70.6% (95% CI: 33.2% to 87.1%) for B. The findings support on-going programme roll-out.

full article

http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=22701